Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lipton, A.
Right arrow Articles by Allard, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipton, A.
Right arrow Articles by Allard, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 6 (March), 2002: 1467-1472
© 2002 American Society for Clinical Oncology

Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer

By Allan Lipton, S.M. Ali, K. Leitzel, L. Demers, V. Chinchilli, L. Engle, Harold A. Harvey, C. Brady, C.M. Nalin, M. Dugan, W. Carney, J. Allard

From the Department of Hematology and Oncology, Penn State Milton S. Hershey Medical Center, Hershey, and Veterans Affairs Medical Center, Lebanon, PA; Novartis Pharmaceutical Corporation, East Hanover, NJ; and Bayer Corp, Tarrytown, NY.

Address reprint requests to Allan Lipton, MD, Department of Medicine, Division of Hematology and Oncology HO46, Penn State Milton S. Hershey Medical Center, 500 University Dr, PO Box 850, Hershey, PA 17033; email: alipton{at}psu.edu

PURPOSE: To determine the effect of elevation of serum HER-2/neu on response to hormone therapy.

PATIENTS AND METHODS: Seven hundred nineteen metastatic patients with estrogen receptor–positive (ER+), progesterone receptor–positive, or both or ER status unknown breast cancer were randomized in three independent clinical trials to receive second-line hormone therapy with either megestrol acetate or an aromatase inhibitor (fadrozole or letrozole). An automated enzyme-linked immunosorbent assay specific for the extracellular domain of the HER-2/neu (c-erbB-2) oncoprotein product was used to detect serum levels.

RESULTS: Two hundred nineteen patients (30%) had elevated serum HER-2/neu protein levels, using the mean + 2 SD (15 ng/mL) from the serum of healthy women as an upper limit. Response to treatment was available for 711 patients. The response rate (complete responses plus partial responses plus stable disease) to endocrine therapy was 45% in 494 patients with nonelevated and 23% in 217 patients with elevated serum HER-2/neu levels (P < .0001). Median duration of treatment response (using the time to progression [TTP] variable for patients who responded) was shorter in the group with elevated serum HER-2/neu levels (11.7 months) compared with the patient group with nonelevated levels (17.4 months). TTP, time to treatment failure, and median survival (17.2 months v 29.6 months) were also significantly shorter in the patients with elevated serum HER-2/neu levels (P < .0001).

CONCLUSION: Patients with ER+ and serum HER-2/neu-positive metastatic breast cancer are less likely to respond to hormone treatment and have a shorter duration of response than ER+ and serum HER-2/neu–negative patients. Their survival duration is also shorter.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. U. Buzdar
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer
Ann. Onc., June 1, 2009; 20(6): 993 - 999.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. F. Leary, W. M. Hanna, M. J. van de Vijver, F. Penault-Llorca, J. Ruschoff, R. Y. Osamura, M. Bilous, and M. Dowsett
Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients
J. Clin. Oncol., April 1, 2009; 27(10): 1694 - 1705.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist, April 1, 2009; 14(4): 320 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Witters, P. Scherle, S. Friedman, J. Fridman, E. Caulder, R. Newton, and A. Lipton
Synergistic Inhibition with a Dual Epidermal Growth Factor Receptor/HER-2/neu Tyrosine Kinase Inhibitor and a Disintegrin and Metalloprotease Inhibitor
Cancer Res., September 1, 2008; 68(17): 7083 - 7089.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
V. Ludovini, S. Gori, M. Colozza, L. Pistola, E. Rulli, I. Floriani, E. Pacifico, F. R. Tofanetti, A. Sidoni, C. Basurto, et al.
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival
Ann. Onc., May 1, 2008; 19(5): 883 - 890.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
V. Kulasingam and E. P. Diamandis
Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines: A Mine for Biomarkers and Therapeutic Targets
Mol. Cell. Proteomics, November 1, 2007; 6(11): 1997 - 2011.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Pietras and D. C. Marquez-Garban
Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers
Clin. Cancer Res., August 15, 2007; 13(16): 4672 - 4676.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Bartsch, C. Wenzel, G. Altorjai, U. Pluschnig, R. M. Mader, M. Gnant, R. Jakesz, M. Rudas, C. C. Zielinski, and G. G. Steger
Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment
Clin. Cancer Res., August 1, 2007; 13(15): 4435 - 4439.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso
Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer
Oncologist, March 1, 2007; 12(3): 253 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. R. Luo, Z. Yang, A. Camuso, R. Smykla, K. McGlinchey, K. Fager, C. Flefleh, S. Castaneda, I. Inigo, D. Kan, et al.
Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure
Clin. Cancer Res., December 1, 2006; 12(23): 7180 - 7186.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. M. Gonzalez-Angulo, G. N. Hortobagyi, and F. J. Esteva
Adjuvant Therapy with Trastuzumab for HER-2/neu-Positive Breast Cancer
Oncologist, September 1, 2006; 11(8): 857 - 867.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Jackisch
HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy
Oncologist, September 1, 2006; 11(suppl_1): 34 - 41.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S.-Y. Kong, B.-H. Nam, K. S. Lee, Y. Kwon, E. S. Lee, M.-W. Seong, D. H. Lee, and J. Ro
Predicting Tissue HER2 Status Using Serum HER2 Levels in Patients with Metastatic Breast Cancer
Clin. Chem., August 1, 2006; 52(8): 1510 - 1515.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. J. Pietras
Biologic Basis of Sequential and Combination Therapies for Hormone-Responsive Breast Cancer
Oncologist, July 1, 2006; 11(7): 704 - 717.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S-Y Kong, J H Kang, Y Kwon, H-S Kang, K-W Chung, S H Kang, D H Lee, J Ro, and E S Lee
Serum HER-2 concentration in patients with primary breast cancer
J. Clin. Pathol., April 1, 2006; 59(4): 373 - 736.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. De Laurentiis, G. Arpino, E. Massarelli, A. Ruggiero, C. Carlomagno, F. Ciardiello, G. Tortora, D. D'Agostino, F. Caputo, G. Cancello, et al.
A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 4741 - 4748.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
H J Huang, P Neven, M Drijkoningen, R Paridaens, H Wildiers, E Van Limbergen, P Berteloot, F Amant, I Vergote, and M R Christiaens
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer
J. Clin. Pathol., June 1, 2005; 58(6): 611 - 616.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. N. Fornier, A. D. Seidman, M. K. Schwartz, F. Ghani, R. Thiel, L. Norton, and C. Hudis
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
Ann. Onc., February 1, 2005; 16(2): 234 - 239.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Ellis
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
Oncologist, June 3, 2004; 9(suppl_3): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Clin. Cancer Res., June 1, 2004; 10(11): 3885 - 3896.
[Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein
Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. J. Kostler, B. Schwab, C. F. Singer, R. Neumann, E. Rucklinger, T. Brodowicz, S. Tomek, M. Niedermayr, M. Hejna, G. G. Steger, et al.
Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer
Clin. Cancer Res., March 1, 2004; 10(5): 1618 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Colomer, A. Llombart-Cussac, A. Lluch, A. Barnadas, B. Ojeda, V. Caranana, Y. Fernandez, J. Garcia-Conde, S. Alonso, S. Montero, et al.
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain
Ann. Onc., February 1, 2004; 15(2): 201 - 206.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Jones
Combining trastuzumab (Herceptin(R)) with hormonal therapy in breast cancer: what can be expected and why?
Ann. Onc., December 1, 2003; 14(12): 1697 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C. P. Price
Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer
Clin. Chem., October 1, 2003; 49(10): 1579 - 1598.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Oncologist, August 1, 2003; 8(4): 307 - 325.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Lipton, S.M. Ali, K. Leitzel, L. Demers, H.A. Harvey, H.A. Chaudri-Ross, C. Brady, P. Wyld, and W. Carney
Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen
J. Clin. Oncol., May 15, 2003; 21(10): 1967 - 1972.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Ozdogan, M. Samur, H. S. Bozcuk, E. Sagtas, M. Yildiz, M. Artac, and B. Savas
Durable Remission of Leptomeningeal Metastasis of Breast Cancer with Letrozole: a Case Report and Implications of Biomarkers on Treatment Selection
Jpn. J. Clin. Oncol., May 1, 2003; 33(5): 229 - 231.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. De Placido, M. De Laurentiis, C. Carlomagno, C. Gallo, F. Perrone, S. Pepe, A. Ruggiero, A. Marinelli, C. Pagliarulo, L. Panico, et al.
Twenty-year Results of the Naples GUN Randomized Trial: Predictive Factors of Adjuvant Tamoxifen Efficacy in Early Breast Cancer
Clin. Cancer Res., March 1, 2003; 9(3): 1039 - 1046.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. Konecny, G. Pauletti, M. Pegram, M. Untch, S. Dandekar, Z. Aguilar, C. Wilson, H.-M. Rong, I. Bauerfeind, M. Felber, et al.
Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
J Natl Cancer Inst, January 15, 2003; 95(2): 142 - 153.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Beltran, R. Colomer, A Lipton, S.M. Ali, and K. Leitzel
Does HER-2 Status Predict Only a Decreased Response to Hormone Therapy in Advanced Breast Cancer, or Does It Also Predict the Extent of Metastatic Disease?
J. Clin. Oncol., December 1, 2002; 20(23): 4605 - 4606.
[Full Text] [PDF]

Home page
 JCOHome page
L. C. Panasci, A. Lipton, S.M. Ali, K. Leitzel, L. Engle, and V. Chinchilli
HER-2/neu Serum Levels Vis-a-Vis Hormonal Response in Metastatic Breast Cancer
J. Clin. Oncol., August 1, 2002; 20(15): 3357 - 3357.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online